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1. Introduction 
Prostate cancer is the most commonly diagnosed cancer in men and the second leading 
cause of cancer related mortality (Byers et al., 2006; McDavid et al., 2004; Sedjo et al., 2007). 
Localized prostate cancer is treated by either radical prostatectomy or radiotherapy. For 
aggressive prostate cancer, hormonal therapy is the standard treatment however; 
approximately 30% of these tumors become hormone–independent (hormone-refractory) 
(HRPC). Furthermore, prostate cancer cells that survive chemotherapy or radiation 
treatment may be able to repair most of the radiation-induced DNA breaks (Kimura et al., 
1999; Kimura & Gelmann, 2000). Therefore, a primary goal in the diagnosis and 
management of prostate cancer is the identification of biomarkers that can reliably predict 
the degree of malignancy of the tumor and can also be used as potential molecular targets to 
improve the response to therapy. This necessity has arisen from the fact that for American 
males, prostate cancer is the most diagnosed neoplasia and the second leading cause of 
cancer-related deaths (Kendal & Mai, 2010; Sajid et al., 2011).  
Risk factors associated with increased prostate cancer incidences include both age and a 
sub-Saharan African ancestry, with African-American men having the highest reported 
incidence rates of all ethnic groups in the United States (239.8 cases/100,000) (Chu et al., 
2003; Odedina et al., 2009). Furthermore, deaths from prostate cancer following surgery are 
more than 2-fold higher in African-American men (56.3/100,000) succumbing to the disease 
compared to white men (23.9/100,000) (Abbott et al., 1998; Chornokur et al., 2011; Talcott et 
al., 2007).  Death from prostate cancer is generally due to metastatic disease that results from 
resistance to treatment such as anti-hormonal therapy. Since African American men are two-
times more likely to die of prostate cancer, identifying the mechanisms that support 
indolent against aggressive disease is an important area of research. 
Increasing evidence suggests that primary and metastatic tumors may be initiated and 
sustained by a subpopulation of low abundance cancer cells with stem-like properties 
(Clarke et al., 2006; Clevers, 2005). These cells, known as cancer stem cells (CSC) or tumor-
initiating cells (TIC), share some characteristics with normal stem cells, such as the potential 
of self-renewal, the capacity to clonally expand, and the ability of multi-lineage 
differentiation (Dalerba et al., 2007; Lang et al., 2009; Weissman et al., 2001). In addition, 
through acquired genetic and epigenetic changes, these cells can exhibit abnormal behavior 
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like increased resistance to apoptosis, decreased senescence, and capacity to escape from 
immune surveillance. All these features can contribute to tumor dissemination, resistance to 
therapy, and disease recurrence.  
There is little doubt that identification and characterization of CSCs is of enormous interest 
because they may provide important information related to the aggressiveness of the 
disease as well as be relevant for the development of targeted drugs to treat metastatic 
tumors and reduce recurrence (Park et al., 2009; Wang, 2007). It is important to note that 
several anticancer therapies are frequently used to eliminate prostate cancer cells; however; 
a number of these cells with malignant phenotypes can survive and may eventually lead to 
tumor regrowth (Dean et al., 2005; Dingli & Michor, 2006). Therefore, the recognition of 
markers for CSC and cell proliferation during the processes of prostate tumor initiation and 
progression is of vital importance to track CSCs for the development and improvement of 
therapies. It is also important to remark that subpopulations of prostate tumor cells with 
cancer progenitor properties are thought to support refractory response to a given 
treatment, leading to prostate tumor recurrence; therefore, new approaches to identifying 
and targeting these cancer subpopulations might provide an avenue to managing metastatic 
and recurrent disease refractive to treatment (Chaffer & Weinberg, 2011; Lang et al., 2009; 
Polyak & Hahn, 2006). This chapter will discuss the potential applications of CSC markers 
that may predict risk of clinical outcome and provide a guide for appropriate therapy of 
prostate neoplasias. 
2. Stem cells in the prostate  
One of the best-accepted models to explain the origin of the different cell types that make up 
a given tissue is the stem cell model (Reya et al., 2001; Weissman et al., 2001).  In this model, 
most of the differentiated cell subtypes that give raise to the tissues can trace their origin to a 
few low-abundance progenitor cells and no longer term tissue maintenance is supported 
through normal adult stem cells that have the capacity for self-renewal and multi-lineage 
differentiation. These stem cells or progenitor cells are characterized by the high expression 
of specific embryonic markers and by a marked degree of plasticity that allows them to 
differentiate into the specific cell types required at a given point in time. According to the 
prostate stem cell model (Isaacs & Coffey, 1989), the progenitor cells reside primarily within 
the basal layer of the prostatic epithelium and have the capacity to give rise to all basal, 
luminal and neuroendocrine epithelial cells (Figure 1).  
Prostate progenitor stem cells are androgen-independent and express high levels of stem 
cell markers (Table 1) such as prominin-1 (CD133), stem cell antigen (Sca1), cluster of 
differentiation 44 (CD44), integrin alpha2beta1 (21) and nestin (Collins et al., 2005; Li et 
al., 2008). As these progenitor cells differentiate into luminal secretory cells, they acquire the 
capacity to express androgen receptor (AR), prostatic specific antigen (PSA), prostatic acid 
phosphatase (PAP), cluster of differentiation 57 (CD57), 15-lipoxygenase 2 (15-LOX2), and 
cytokeratins 8 (CK8) and 18 (CK18). When the adult stem cells commit instead to the 
generation of non-secretory basal cells, they primarily express CD44, tumor protein 63 (p63), 
cytokeratin 5 (CK5) and 14 (CK14) but not AR, PSA, and PAP (Liu et al., 1997; Signoretti et 
al., 2000). There is a cell subtype intermediate between basal and luminal that shows 
expression of the CK5, CK8 and CK18 but not CK14 (Schalken, 2005). Neuroendocrine (NE) 
cells are found dispersed throughout the epithelium and can be identified by their 
expression of chromogranin A, synaptophysin, and neuron-specific enolase (NSE) (Bonkhoff 
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et al., 1995; di Sant' Agnese, 1996). NE cells also express some peptide hormones such as 
somatostatin, calcitonin and serotonin. However, they do not express AR or PSA. The 
prostate also contains several types of stromal cell including fibroblasts, myofibroblasts, and 
smooth muscle cells that guide the growth and differentiation of the epithelium.  
 
 
Fig. 1. The prostate epithelium niche contains a low percentage of prostate stem cells that 
express embryonic markers and are capable of generating the different cellular types, which 
compose this microenvironment. Cell types that are believed to arise from the differentiation 
of prostate stem cells are the basal, NE cells, and luminal secretory cells. Intermediate cells 
are believed to be a transitional type between basal and luminal cells. 
The debate regarding the location, phenotype, number, nature, and presence of stem cells in 
the adult prostate still persist. However, consistent evidence supporting the existence of SC 
in the prostate has been reported in adult rodent prostate (English et al., 1987; Hudson, 2003; 
Miki, 2010). After several rounds of castration-induced regression and testosterone-induced 
regeneration in this animal model, a small proportion of cells (CSCs), were able to 
proliferate and also gave rise to differentiated and non-proliferative glandular epithelial 
cells. Although, the majority of luminal cells undergo apoptosis after androgen deprivation, 
the remaining androgen-independent epithelial cells contain a high proportion of basal cells 
(Montpetit et al., 1988; Webber et al., 1997a, 1997b). After regression, the remaining 
epithelial population appears to regenerate the prostate following androgen replacement.  
The cycle of prostatic involution and regeneration can be repeated many times, indicating 
that the androgen-independent stem cells survive androgen deprivation and have an 
extensive proliferative and regenerative capacity, as well as multipotency. The identification 
and utilization of different types of biological markers in different in vivo models has led to 
the hypothesis that prostate stem cells reside within the basal cell layer of the gland. Indeed, 
mice null for p63, the progenitor gene for the tumor suppressor p53 family, are born without 
prostate or mammary glands (Mills et al., 2002; Signoretti et al., 2000). Both progenitors and 
basal cells of the prostate express p63, however this protein is lost during prostate 
differentiation and is not expressed in malignant prostatic lesions (Signoretti et al., 2000).  
In humans prostate basal cells express B-cell lymphoma 2 (BCL2), an anti-apoptotic protein 
that is frequently expressed by stem cells and is inversely related to androgen stimulation 
(Lu et al., 1996). While administration of a pulse of bromodeoxyuridine (BrDU) identifies 
rapid proliferating transit-amplifying cells in the luminal compartment, a region that is close 
to the urethra, and also contains stem cells (Tsujimura et al., 2002). Because stem cells are 
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maintained in a quiescent state, the high expression of transforming growth factor beta 
(TGF-) by smooth muscle cells that form the proximal region of the prostatic ducts was 
proposed as a mechanism that modulates proliferation of prostatic epithelial stem cells. 
Indeed, blocking of TGF- expression in the prostate induced an excessive proliferation of 
prostatic epithelial cells in the proximal region of the prostate (Kundu et al., 2000). 
Additional observations have shown that stem cells are also located in different regions of 
the prostate, which have the ability to survive androgen ablation and can regenerate 
prostatic tissue after androgen is replaced (Goto et al., 2006). 
 
Markers expressed by prostate epithelial cells
Stem Cells 
 
CD133+ 
CD117+ 
CD49f+ 
nestin+ 
21+ 
ALDH+ 
Trop-2+ 
CK5+ 
CK8+ 
CK14+ 
CK18+ 
CK19+ 
AR- 
p63- 
PSA- 
PAP- 
Basal 
Cells 
p63+ 
CD44+ 
CD117+ 
CK5+ 
CK14+ 
AR- 
PSA- 
PAP- 
 
Neuroendocrine 
Cells 
AR- 
CK18+ 
chromogranin A+ 
synaptophysin + 
serotonin+ 
somastostatin+ 
Intermediate 
Cells 
CD133+ 
21+ 
CK5+ 
CK8+ 
CK14- 
CK18+ 
Luminal 
Cells 
AR+ 
CK8+ 
CK18+ 
CD57+ 
PSA+ 
PAP- 
p27+ 
Sca1 
Table 1. Complex expression of markers associated with different prostatic epithelial cells 
The prolonged regenerative capacity of prostate progenitor stem cells may increase their 
susceptibility to accumulate genetic or epigenetic alterations during their life cycle, events 
that may help to promote increased proliferative rates, decreased cell death, and overall 
survival advantages over prostate progenitor stem cells, contributing thus to transformation 
(Al-Hajj & Clarke, 2004; Bapat et al., 2005; Beachy et al., 2004; Miller et al., 2005; Mimeault & 
Batra, 2006b, 2007a; Odedina et al., 2009). The tumor associated stem cell compartment may 
therefore, represent a self-replicating reservoir of malignant cells, which may accumulate 
further genetic and epigenetic aberrations that can thus result in therapy-resistant, tumor 
recurrence and/or metastasis (Hsieh et al., 2007; Rajan et al., 2009; Witte, 2009). It is believed 
that tumor stem cells maintain many of the features and capabilities of their normal 
counterpart, including long-term self-renewal and multipotency. Stem-like functions of 
CSCs inherited from their normal stem cells counterparts may be critical for survival during 
long periods of time in tissues (Hsieh et al., 2007; O'Brien et al., 2010; Rajan et al., 2009; 
Rosen & Jordan, 2009; Vermeulen et al., 2008; Witte, 2009). In this regard, the generation of 
cancer cells and their success in tumor growth are probably dependent on dysregulations 
affecting cells with stem-like characteristics and have the ability to promote tumor and 
support tumor development (Dalerba et al., 2007; Lang et al., 2009; Weissman et al., 2001). In 
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fact, malignant tumors, like normal tissue, frequently contain cells at various stages of 
differentiation, a mechanism that mimics dedifferentiation of mature cell types and 
presumes a hierarchical organization (Clarke et al., 2006; Clevers, 2005). Because there is the 
possibility that CSCs share various signaling characteristics with normal stem cells, several 
methods are frequently utilized to identify putative CSCs in human prostate cancer tissues, 
human and animal cell lines, and in vivo cancer animal models. 
3. Assaying prostate cancer stem cells  
The determination of cancer stem cells in primary tumors is a difficult task, with many 
variables and potential for confounding results. CSCs constitute a minority proportion of 
the constituent cells of tumors, and therefore their analysis can only be undertaken after 
isolation and propagation in tissue culture or in vivo systems. Several methods are being 
used to identify, enrich, and propagate these tumor cells and to study their biology as 
crucial players in tumorigenesis (Table 2).  
3.1 Enrichment of CSCs from cancer cell lines and primary tumors 
Human immortalized prostate cancer cell lines have been accessible and frequently utilized 
as biological models to investigate cancer biology and to test the efficacy of potential 
anticancer drugs. Most of cancer cell lines available have been continuously cultured under 
different conditions, and only a minor percentage of cells preserve their clonal growth, 
clonogenic potential, and the ability to form tumors when transplanted in animal hosts. 
Criticisms to cancer cell lines arise due to the high potential for culture contamination by 
other cell lines (Borrell, 2010; Li et al., 2009). These cells represent highly selected subgroup 
of cells that may have accumulated additional genetic abnormalities as they adapt to an 
artificial environment. Nevertheless, the utilization of cancer cell lines is an important tool 
used by researchers to study CSCs and carry out mechanistic studies.  
Following isolation, analysis of CSCs is performed by culturing primary tumor cells in vitro, 
either as monolayers or as spheres, both of which are particularly difficult in the case of 
prostate cancer cells derived from primary tissues (Miki et al., 2007; Tokar et al., 2005). 
Indeed, most human prostate cancer cell lines utilized to dissect the events associated to 
cancer progression and metastasis has been established from metastatic lesions or from 
xenograft tumors (Sobel & Sadar, 2005a, 2005b). An efficient cell immortalization culture 
based on the inhibition of the serine/threonine kinase ROCK have been shown to reversibly 
immortalize primary human keratinocytes and to increase the cloning efficiency of murine 
prostate cells (Chapman et al., 2010). Since immortalized keratinocytes are genetically and 
functionally similar to the primary tissues they were derived from, this method is an 
advance over the traditional procedures that promote genetic changes.  Strict parameters 
defining CSCs require that upon isolation these cells exhibit certain biological characteristics 
such as self-renewal and proliferative potential, as well the capacity, under the proper 
conditions, to differentiate into other cell types. These capabilities can be determined in vitro 
through the use of colony formation assays. However, the stem-like features of these cells is 
confirmed through experimental approaches in which these cancer cells in a very low 
number have the capacity to generate tumors in in vivo systems.  
The most commonly used in vivo system used to propagate these tumorigenic cells are 
xenograft models, either subcutaneous in the renal capsule or orthotopic. For these isolated 
putative CSCs to be established as such, certain conditions must be met. Isolation of CSCs 
www.intechopen.com
 
Prostate Cancer – From Bench to Bedside 
 
498 
should be capable of generating a tumor in vivo, and successful serial transplantation of 
these tumors must be possible for several generations. Importantly, a number of variables 
that can affect the outcome of these in vivo assays includes: the manner in which cells are 
isolated; whether these cells are initially propagated in vitro before transplantation, which 
can cause them to become more aggressive as a result of new acquired mutations; the 
procedure employed to inoculate the mice; the strain of mice employed, etc, that is often 
taken, in particular during the experimental planning phase and analysis process. 
 
Assaying Prostate Cancer Stem Cells 
Isolation through stem cell markers expression 
CD44+ 
Integrin 12+ 
CD133+ 
CD44+/12+ 
CD44+/CD24- 
12+/CD133+ 
CD44+/12+/CD133+ 
 
Isolation of cancer stem cells 
Established human cancer cell lines 
Fresh human surgical samples 
Culture in ultra-low attachment surface 
Isolation of holoclones 
Limiting dilution assay 
Hoechst 33342 dye and exclusion 
Rhodamine 123 
 
Methods to measure proliferation, growth rate, invasion 
Fluorescent activated cell sorting 
Matrigel invasion 
Matrigel 3-D culture 
Sphere formation anchorage independent growth protasphere  
 
Methods to identify gene signatures and/or protein expression 
Microarray 
Quantitative RT-PCR 
Sequencing 
Tissue microarray 
Flow cytometry 
Immunohistochemistry 
Immunofluorescent analysis 
Immunoblotting 
Animals models (into immunocompromised mice) 
Transplantation 
Xenografts 
Table 2. Methods utilized for the enrichment of prostatic cancer stem cells. 
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3.2 Determining the frequency of CSCs based on limiting dilution assay and 
spherogenecity 
The rarity of cancer stem cells within the tumor bulk in many cases makes the utilization of 
the limiting dilution assay (LDA) necessary. This type of analysis has the ability to estimate 
the frequency of CSCs among a population of cancer cells (Hope & Bhatia, 2011; Schroeder, 
2011). LDA can also be utilized to estimate the ability of a single tumor cell to form 
spheroids in serum-free cultures. Importantly, to reduce possible variations and calculate 
the frequency of CSCs, LDA needs to be tested in both bulk and fractionated cancer cells for 
each individual tumor (O'Brien et al., 2010). Since CSCs are a rare population with low 
numbers of cells, the injection of unsorted tumor cells into mice has been used to expand 
these cancer cells before applying LDA. It is important to consider that even if serial 
dilutions of tumor cells are injected into groups of animals, the development of a tumor in a 
recipient animal implies that the inoculum contained at least one reproductively intact cell 
(Porter & Berry, 1963). The LDA can also provide important information regarding the 
existence of cooperation among tumor cells that may be critical for the surviving and 
proliferation of cells that generate a tumor, therefore validating the existence of a single CSC 
(Hu & Smyth, 2009). 
Several experimental approaches are being utilized to study the properties of cancer stem 
cells in vitro. For example, utilizing low adherence cultures, growth in soft agar, suspension 
cultures, and the use of ultra low adherence plates. In general, a serum-free media 
containing epidermal growth factor (EGF) and fibroblast growth factor (FGF), specifically 
formulated for the culture of pure populations of stem cells, is utilized to enrich and grow 
putative CSCs (Tropepe et al., 1999). The success of these methodologies is quite relative. 
Because the cells grow in these stringent conditions cannot be kept in culture for long 
periods of time. Recent evidence has demonstrated that sphere cells with stem-like 
properties from prostate cancer cells can be generated and propagated without the addition 
of growth factors (Rybak et al., 2011). This new culturing condition also supported a long-
term culture of prostate stem-like cells, adding an important tool to investigate the biology 
and the expression of specific cell surface markers in CSCs. Similarly, inhibition of ROCK 
activity in culture (Chapman et al., 2010) enabled an 8-fold increase in in vitro prostate 
colony assay, and also significantly increased the cloning efficiency of prostate stem cells 
from mice (Zhang et al., 2011). 
3.3 Protaspheres 
The utilization of spheres assay is an important tool for the in serial in vivo transplantation 
to verify self-renewal potential. Although, sphere cells are generated, serially passaged, and 
maintained in undifferentiated phenotype under appropriate cell culture conditions, they 
need to be inoculated into animal models to confirm their ability to generate tumor growth. 
In this regard, it is necessary to ensure the best animal model available in order to reproduce 
tumor CSCs biology as it occurs in humans. It is important to note that variation on 
experimental conditions would certainly influence frequency estimates. In fact, it was 
suggested that limiting dilution data might be dramatically affected by the duration of data 
analysis (Yamazaki et al., 2009) or by modification of xenotransplantation assay in non-
obese diabetic severe combined immunodeficient (NOD/SCID) mice (Quintana et al., 2008). 
Therefore, a main concern for the application of this methodology is that sometimes, the 
animal models overstate the biology of cancer formation in humans. 
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Prostate cancer cell lines are frequently used to investigate the mechanisms that modulate 
protaspheres in non-adherent cultures. Several reports have shown that most of these cells 
have the ability to form spheres; however, the frequency of cells that form spheres is very 
heterogeneous across all cell lines. It is possible that adaptation of these cells to non-
adherent culture conditions may be a determinant in forming spheres (Bisson & Prowse, 
2009). It has also been shown that holoclone-forming cells, cells whose progeny forms 
almost exclusively growing colonies, in prostate cancer specimens with the highest 
clonogenic potential were associated with stem cell phenotypes (Patrawala et al., 2007). 
More, the presence of large holoclones was also consistently observed in prostate cancer cell 
protaspheres (Li et al., 2008; Zhang & Waxman, 2010), suggesting that spheres with stem 
cell-like features have a higher proliferative potential. Indeed, protaspheres were capable of 
forming new generations of protaspheres and retained proliferative capacity as well as 
clonogenic potential after serial passages (Guzman-Ramirez et al., 2009).  
3.4 Identification of cancer stem cell signatures using microarray technology 
The utilization of microarray analysis has allowed for screening the expression profile of 
numerous genes in prostate tumors (Glinsky, 2007; Mendes et al., 2008; Witte, 2009). By 
using gene expression microarray technology, the expression levels of thousands of genes 
are analyzed in a single experiment and evidences of certain degree of relevance to cancer 
progression may be also obtained (Borst & Wessels, 2010; Witte, 2009; Zieger, 2008). 
Because cancer cells and somatic stem cells share the biological characteristics of self-
renewal and proliferation, the principles of stem cell biology can be applied to improve 
our understanding of cancer biology (Liang et al., 2009). Although several cell surface 
markers have been utilized for the isolation of putative cancer stem cells, the 
identification of key molecules and pathways that play pivotal roles in prostate cancer 
progression towards an aggressive stage is crucial for a more precise prognosis in patients 
with prostate cancer (Ladanyi, 2008; Rubin, 2008). As a matter of fact, the identification of 
molecular signatures has allowed the identification of androgen subtypes of cancers that 
have not been distinguished by pathological criteria (Alizadeh et al., 2009; Goodison et al., 
2010; Perou et al., 2010; Wegiel et al., 2010; Yang et al., 2010) and in prostate tumors, the 
microarray technology has identified androgen-regulated genes in prostate tumor models 
(Elek et al., 2000).  
Laboratory animals have been used to mimic natural aspects of human prostate cancer 
development. The evaluation of gene expression in samples derived from these animal 
models has  provided for the identification of gene signatures, which are represented in the 
altered expression in a large group of genes (Ladanyi, 2008; Mendes et al., 2008; Witte, 2009). 
These data can be useful to compare in vitro results with intact animal expression changes 
and the different signatures that may eventually be predictors of cancer progression. More 
recently, a major effort towards this end addresses global analyses of gene expression 
profiles. However, the large body of data sometimes does not provide clear information 
about the specific genes that may be associated with the aggressive growth of prostate 
tumors. In this regard, the identification of poor prognosis using an interspecies comparison 
of prostate cancer gene-expression profiles has been a valuable tool to predict the 
association of potential oncogenic events to an aggressive phenotype of prostate cancer 
(Kela et al., 2009).  
Because gene expression is a complex process characterized by a high degree of regulation, 
studying which genes are active and which are inactive during tumor progression helps to 
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understand both how these cells may function normally and how they are affected when 
several genes do not perform properly. In addition, gene expression profiles can provide key 
information in the identification of a signature that can be used to assess corresponding 
biological responses in other potential candidate(s), which may be indicative of cancer 
progression effects and pathological endpoints (Goodison et al., 2010; Hsieh et al., 2007; 
Mendes et al., 2008). Therefore, there is no doubt that microarray technology is a new tool for 
the clinical lab and also can improve the accuracy of classical diagnostic techniques by 
identifying potential novel tumor specific markers. Therefore, it is important that microarray 
data be publicly available. The establishment of specific criteria is important to identify genes 
associated to diseases. This may facilitate the classification by the identification of only 
relevant genes, improving the tumor classification accuracy and reducing the 
dimensionality of the data set (Wang et al., 2005). 
3.5 The side population dilemma to isolate CSCs 
An innovative approach frequently utilized to isolate stem cells is the side population (SP) 
assay (Goodell et al., 1996). This controversial technique had generated excitement because 
of its enormous potential to isolate putative CSCs. Cells with and SP phenotype, which is 
associated with primitive and undifferentiated stem cells characteristic are enriched based 
on their highest efflux activity to dyes such as Hoechst 33342 or Rhodamine 123. This 
approach had allowed the identification of a small subset of quiescent and replicating 
Hoechst-staining CD34-negative in murine cells that efflux the dye, allowing defined 
separation of this subset from the rest of the bone marrow (Goodell et al., 1996). This subset 
presented a very homogeneous pattern compared to cell surface markers. Using this 
approach, a subset of cells with similar phenotype to mouse was also identified in human 
bone marrow. This conserved SP phenotype was proposed as a common molecular feature 
for stem cells possessing multi-organ plasticity. The assessment of the molecular basis for SP 
phenotype found that the ATP-binding cassette (ABC) protein breast cancer resistant 
protein (Bcrp1) transporter expression is highly conserved in primitive stem cells from 
murine bone marrow, skeletal muscle, and cultured ES cells. While Bcrp1 expression is 
exclusive of the primitive subset CD34+ and was developmentally regulated, enforced 
expression of Bcrp-1 expanded the SP phenotype in bone-marrow cells (Zhou et al., 2001).  
Other ABC transporters, including the multidrug resistance 1 (Mdr1a/1b, mouse; MDR1, 
human) and the multidrug resistant protein (MRP) are also able to efflux Hoechst 33342, 
which have been indicated as contributors for multidrug resistance of tumor cells (Schinkel 
et al., 1997). However, in the Mdr1a/b/Bcrp1 triple knockout mice model, some bone 
marrow cells still retained the SP phenotype. This redundancy suggested that the influence of 
transporters in the SP phenotype is probably not exclusive on the expression of ABC 
transporter proteins. Latter experiments using knock down of the Bcrp1 gene expression 
animal model proved that the Bcrp1 gene, and not Mdr1a/1b, drastically reduced the number 
of SP cells in the bone marrow and in skeletal muscle. This study also evidenced that Bcrp1 
expression is crucial in protecting early hematopoietic cells against chemotherapeutic drugs 
such as topotecan, mitoxantrone, or 5-fluorouracil (5-FU) (Zhou et al., 2002).  
It has been proposed that the lower affinity of MDR-1-encoded transporter rather than the 
ATP-binding cassette, sub-family G (WHITE), member 2 (ABCG2) transporter for the 
Hoechst dye may explain its reduced effect in the SP phenotype. Indeed, enforced 
expression of a MDR1 retroviral vector in murine bone marrow cells in vitro increased SP 
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cells only to 3.6% of the total population (Bunting et al., 2000), a very low percentage 
compared with the impressive levels provided when the ABCG2 vector (62.5% SP cells) was 
utilized (Zhou et al., 2001). In fact, SP cells isolated from normal prostate tissues isolated 
from radical prostatectomy were enriched in ABCG2 expression. The gene expression 
signature of the ABCG2 subpopulation showed a consistent number of markers associated 
with stem-like phenotype (Pascal et al., 2007), suggesting the feasibility of the SP assay to 
identify and isolate cells with stem-like phenotype in the prostate. 
Reports associating SP cells with tumorigenicity and/or aggressiveness have also been 
established in many tissues including breast, colorectal, glioma, medulloblastoma, ovarian, 
and thyroid (Chiba et al., 2006; Hirschmann-Jax et al., 2004; Kondo et al., 2004; Mitsutake et 
al., 2007; Szotek et al., 2006). In prostate tumor cell lines and human tissues, the utilization of 
the SP assay has also allowed the enrichment of cells with stem-like characteristics, which 
expressed high levels of different types of transporters such as ABCG2, ATP-binding 
cassette, sub-family A (ABC1), member 2 (ABCA2), MDR-1 and MRP-1 (Mathew et al., 2009; 
Oates et al., 2009; Patrawala et al., 2005). The prostate cancer SP phenotype possessed self-
renewal capacities in vitro and in vivo intrinsic properties of stem cells as evidence by the 
activity of Wnt and Hedgehog signaling pathways, high proliferation rate, and tumorigenic 
potential ((Bhatt et al., 2003; Brown et al., 2007; Patrawala et al., 2005). These findings 
implied that the SP subpopulation is enriched with tumorigenic stem-like cancer cells that 
may be resistant against therapies.  
Cells with stem-like characteristics have also been enriched in SP subsets but were not 
exclusive for breast, thyroid, and breast cancer cell lines in which some of the non-SP cells 
had the ability to generate cells with SP phenotypes (Mitsutake et al., 2007; Patrawala et al., 
2005). Interestingly, non-SP cells also preserved their tumorigenic potential. Although 
contamination might be responsible for these unexpected results, a critical concern in this 
endeavor is that SP assay does not isolate cells by a definitive cell surface profile; because of 
that, the population being isolated is very heterogeneous (Challen & Little, 2006). It was also 
reported that both SP and non-SP fractions from malignant mesothelioma and lung 
adenocarcinomas cell lines were also equally able to form spheres, have a high tumorigenic 
potential, and are resistant to chemotherapeutic agents (Pan et al., 2010). More intriguing 
was the fact that no evidence of stem-like characteristics was found in gastrointestinal 
cancer cell lines in which lifespan in tissue culture and tumorigenesis potential are not 
exclusively associated with the SP phenotype (Haraguchi et al., 2006). This leads to the next 
question: are other types of cells also involved in key events during cancer evolution? These 
results also indicate that the SP assay is not appropriate for the identification and 
enrichment of putative CSCs in lung tumors (Kai et al., 2010).  
Together, these results raise the inevitable question: is it correct to affirm that SP enriches a 
subpopulation with potential stem-like characteristics? One potential explanation for these 
conflicting results was provided by the kinetic analysis of Hoechst 33342 on bone marrow 
over a dye incubation period (Ibrahim et al., 2007). This approach demonstrated that bone 
marrow nuclear cells evidenced an identical staining pattern at varying rates, even under 
conditions where SP fraction was depleted, suggesting that the SP phenotype is not unique 
to stem cells. These data may be indicative of a transient feature of marrow cells when 
exposed to Hoechst 33342 for varying amounts of time. It is also possible that cells not 
exhibiting SP phenotype may have their membrane pumps overwhelmed or perhaps the 
dye efflux mechanism is inactivated. 
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All the biological assays discussed above may have important clinical implications. Indeed, 
proliferation assays could be included in the routine assays of pathologists to provide the most 
accurate diagnosis to patients with prostate cancer. As a matter of fact, the grading of prostate 
tumors (low versus high) is analyzed based on tubule formation, nuclear grade, and mitotic 
count. The mitosis cell evaluation is carried out basically by scoring the number of mitotic cells 
present within a giving sample. Considering that the worst histologic grade dictates the 
biologic behavior of prostate cancer (Chan et al., 2000; Harnden et al., 2007; Hattab et al., 2006; 
Pan et al., 2000; Sim et al., 2008), the inclusion of appropriate assays to identify proliferative 
signatures may improve the clinical diagnosis/prognosis of prostate cancer that may help to 
reduce misdiagnosis, missed diagnosis, or decrease the rates of overdiagnosis.  
4. Prostatic cancer stem cells 
A challenge in studying solid neoplasias is the heterogeneity observed in the tumor bulk 
where multiple cell types coexist, each exhibiting unique proliferation rates, invasion, and 
metastatic potential. This is the result of diverse combinations of genetic and epigenetic 
aberrations that arise from stressors such as inflammation, oxidative stress, aging and 
environmental influence. 
Although several commonly mutated genes involved in the tumorigenesis process have 
been identified, there is no clear evidence that the transformed cells specifically responsible 
for tumor initiation and maintenance of solid malignant neoplasias have been clearly 
identified or isolated thus far. Therefore, it is crucial for the understanding of cancer 
evolution to provide new insights into the molecular mechanisms by which CSCs modulate 
cancer development. In this respect, efforts are being made toward the identification of 
reliable biomarkers (Keysar & Jimeno, 2010; Marhaba et al., 2008; Zoller, 2011) for the 
accurate identification of malignant progenitor tumor cells and also to use them as possible 
molecular targets to improve response to therapy. These potential markers of stem cells or 
CSC markers obviously preserve specific biological functions, but these have yet to be 
discovered as only limited research has been conducted to explore the process of their roles 
in tumor initiation and progression. Moreover, the limited number of cancer stem cells 
within the tumor, the heterogeneity of androgen receptors, the phenotypic characteristics of 
the tumor bulk and different genetic signatures are also important aspects that restrict the 
identification of this unique subset of cancer cells in prostatic cancer. 
Numerous reports have described several types of tumors including prostate cancers, 
biological markers that can recognize a small population of cancer cells in the tumor bulk 
with stem-like characteristics (Miki et al., 2007; Patrawala et al., 2006; Patrawala et al., 2007; 
Vander Griend et al., 2008). Many of these markers associated with stem cells are cell surface 
proteins (i.e., CD44, CD133, CD166, etc), which is facilitating the identification of tumor 
subpopulations with stem-like phenotypes. In addition, signaling pathways activated by the 
core pluripotent transcription factors Nanog, Oct4, and Sox2, which are very important 
components of the machinery that modulates cell-renewal and maintains pluripotency in 
both embryos and stem cells, are also frequently overexpressed in poorly differentiated 
tumor cells (Jeter et al., 2009; Jeter et al., 2011). However, the nuclear localization of these 
transcription factors precludes their utilization for the enrichment of CSC. 
Cancer stem cells have been enriched from human cancer prostate based on the expression of 
21 integrin or CD133 (Collins et al., 2005). In addition, holoclones from the prostatic cell line 
PC3 that were tumorigenic in xenograft assays showed increased expression of 21, -
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catenin, and CD44 (Li et al., 2008). Although CD44 expression was also associated with 
enrichment of cancer stem cells in other prostatic epithelial cell lines, this subset of cells 
displayed low efficiency in formation of xenograft tumors (Hurt et al., 2008; Patrawala et al., 
2007). Prostate tumor cells expressing the CD133 isolated from 21hi cells were capable of 
expanding in culture. These prostatic putative stem cells were able to drive the reconstitution 
of prostatic-like acini in immunocompromised male nude mice (Richardson et al., 2004). Even 
when controversial reports have challenged the role of CD133 as a cancer stem cell marker, 
several evidences have supported that CD133 expression is generally detected in prostate 
cancers (Guzman-Ramirez et al., 2009). In fact, this subset of cells had the ability to form 
protaspheres from single cells. However, protaspheres generated from freshly isolated cancer 
prostate cells that were either CD133+ or CD133-, suggested that neoplastic transformation can 
confer self-renewal potential also to CD133- progenitor cells (Tang et al., 2007).  
A comparison of clonogenic cells isolated from primary prostate cancer populations 
identified only tumor-derived 21high/CD133+/CD44+. This cellular subpopulation also 
presented a phenotype similar to normal prostate stem cells and was also capable of self-
renewal and extensive proliferation compared to more differentiated cells did not form in 
vitro secondary colonies (Collins et al., 2005). The differentiation of this subpopulation with 
serum and dihydrotestosterone to an androgen receptor-positive phenotype promoted in 
these cells the expression of AR+/PAP+/CK18+, which suggests that they were derived from 
a more primitive multipotent population of CSCs. In support for these findings, Patrawala 
et al., (Patrawala et al., 2006) reported that a highly purified CD44+ prostate cancer subset 
from xenografts of a human tumor, as well as from multiple cultured cell lines are enriched 
in tumorigenic and metastatic progenitor cells. The CD44+ subpopulation was more invasive 
than CD44- cells and also expressed high levels of several stem-like genes such as Oct3/4, 
Bmi, and -catenin.  
In addition, clonally derived human prostate cancer specimens from epithelial cell lines 
expressing the embryonic stem markers Nanog, Oct4, and Sox2 as well as other early 
progenitor cell markers such as CD44, CD133, c-kit, and Nestin were able to recapitulate 
human prostate tumors in SCID mice and were also categorized according to Gleason score 
(Gu et al., 2007). In fact, these cell lines formed tumors that contained basal, luminal, and NE 
epithelial cell lineage of the prostate, and retained their capacity of proliferation through 
serial transplantations. This is consistent with studies showing that high levels of Nanog is 
expressed in human primary prostate cancers cells and it also have a functional role for 
tumor growth (Jeter et al., 2009; Jeter et al., 2011). Interestingly, the putative prostate cancer 
stem cells do not express AR and p63, similar to that reported for prostate stem cells 
(Barbieri & Pietenpol, 2006; Rizzo et al., 2005). In support of these findings, increased 
expression of CD133 and the stromal cell-derived factor-1 receptor (CXCR4) were detected 
in a subpopulation of clinical prostate specimens that do not express AR (Miki et al., 2007). It 
is therefore conceivable to predict that the heterogeneous nature of prostate cancer, a 
common characteristics of this disease may have a stem cell compartment. Therefore, it is 
unlikely that a single marker can be used for the identification of cancer stem cells’ 
subpopulations within the tumor mass.  
5. Therapy targeting prostate cancer stem cells 
The dysregulation of the cell cycle regulatory machinery that impact tumor cell proliferation 
also participates in the accelerated growth observed in most malignant tumors. Although 
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the exact genes that comprise the proliferation status may differ in different type of tumors, 
evidence has demonstrated that the cell cycle regulation is frequently altered in prostate 
cancers, in part, by the interplay of activation of oncogenic cascades with diverse hormones, 
growth factors, and cytokines. These events may eventually lead to a more poorly 
differentiated and aggressive tumor behavior, leading to overall higher rates of progression 
and worse prognosis, irrespective of the size of the lesion (Flavin et al., 2010, 2011; Niu et al., 
2010; Saeki et al., 2010). Therefore, inhibitors of cell cycle regulatory proteins has become an 
area of increased interest in targeting both cancer cells per se and CSCs (Malumbres & 
Barbacid, 2009). For example, we have recently demonstrated the efficacy of a novel 
dansylated VMY-1-103, a CDK1, CDK2 inhibitor, based on purvalanol B (Ringer et al., 2010), 
at very low concentrations in inhibiting Erb-2/Erb-3/heregulin-induced cell proliferation in 
LNCaP prostate cancer cells. It was also observed that VMY-1-103 induced apoptosis via 
decreased mitochondrial membrane polarity, induced p53 phosphorylation, caspase-3 
activation, and PARP cleavage in these prostatic tumor cells, which express p53 wild type. 
More, VMY-1-103 was also effective inducing cell cycle arrest in prostate cancer cell lines 
compromised for p53 function, however, VMY-1-103 failed to induce apoptosis in p53-null 
prostate cell lines PC3 (Ringer et al., 2010). These results, strongly suggest that VMY-1-103 may 
be an effective therapeutic, either alone or in combinations with other drugs, in treating 
prostate cancer. Importantly, we have also found that VMY-1-103 is also effective in inducing 
apoptosis in spheroid cultures (Ringer et al., unpublished data). Given the critical role of CDK1 
in proper timing of mitosis in all cells, VMY-1-103 may also be able to efficiently target CSC’s, 
and this exciting possibility is being addressed both in vitro and in vivo. 
Cancer usually treated using chemotherapy, radiotherapy, or surgery had limited effect on 
most primary tumors, which have already spread to other organs, leading to recurrent 
disease in the majority of patients. The reduced number of individuals that benefit of 
standard therapies may be improved with targeted clinical trials (Simon & Maitournam, 
2004). In this respect, the identification of potential biological markers by microarray or 
sequencing technologies would help to restrict the number of patients that might response 
to a specific drug. However, the limited knowledge in tumor cell biology, in which 
multiples abnormalities need to be targeted simultaneously make difficult to predict which 
patients are most likely to respond to a given regimen (Sparreboom & Verweij, 2009; 
Woodward & Sulman, 2008). For instance, the significant therapeutic advances in patients 
with diverse types of localized cancers have been limited by relapse due to the persistence of 
cancer cells in primary tumors and micrometastases that may have intrinsic or acquisition of 
a resistant phenotype to current therapies available (Gray-Schopfer et al., 2007; Mimeault & 
Batra, 2006a, 2007b; Mimeault et al., 2007; van Leenders et al., 2001; Yang et al., 2010). 
Despite recent therapeutic approaches that have significantly increased survival, most 
prostate aggressive tumors become resistant to current treatment protocols and the 
proportion of cancers that progress is significantly higher in the African American 
population (Chornokur et al., 2011; Gurel et al., 2008). Prostate cancers that initially respond 
to standard chemotherapy often recur with selective outgrowth of tumor cell 
subpopulations that are resistant not only to the original chemotherapeutic agents but also 
to other therapeutics. Thus, for example, most patients that relapses with castration-resistant 
cancer metastatic tumors for which there are no curative treatment. In this regard, it has 
been suggested that the cancer stem cell model may be responsible for the degree of 
sensitivity to anti-androgen therapy (Schalken, 2005). Although different cellular events 
involving pathways may effectively activate a different path to androgen independence 
www.intechopen.com
 
Prostate Cancer – From Bench to Bedside 
 
506 
probably through a paracrine androgen-independent pathway, the multifocality and 
heterogeneity of prostate cancer may also account for hormone therapy resistance. In a 
human prostate cancer progression xenograft model, most of androgen-responsive genes 
that were initially downregulated under conditions of androgen deprivation were later re-
expressed in recurrence tumors, indicating failure of androgen-derivation therapy as well as 
acceleration of tumor progression (Mousses et al., 2001). Another microarray-based profiling 
found that increase in AR transcript, as well as protein levels are essential for accruing 
resistance to anti-androgen therapy (Chen et al., 2004). Indeed, multiple cellular signaling 
pathways including AR, Akt, mitogen-activated protein kinase (MAPK), the nuclear factor 
kappa B (NF-B), TGF-, vascular endothelial growth factor (VEGF), and Wnt have been 
shown to enhance AR signaling and confer development of hormone-
independent/castration-resistance in preclinical models (Mellado et al., 2009; Wegiel et al., 
2010). More recently, it has been reported that Nanog induction promoted castration-
resistant tumor phenotype and tumor regeneration in the human tumor cell line LNCaP. 
These findings support the notion that AR expression in prostate tumors is modulated by 
CSCs (Maitland & Collins, 2008). 
The most challenging problem in prostate cancer is the identification of which cell or cells 
are transformed and initiate carcinogenesis. In addition, tumor heterogeneity appears to 
mask a minor tumor population (CSCs) that have the ability to self-renew and form a tumor 
but are typically in a quiescent state. This has been suggested as a critical mechanism by 
which CSCs are resistant to conventional chemotherapy or radiation treatments. Thus, 
prostate CSCs are likely to modulate resistant to androgen deprivation therapy and promote 
recurrence as hormone-refractory tumors and metastatic lesions. Even though prostatic 
CSCs do not express AR or PSA (Lawson & Witte, 2007; Tang et al., 2007), it appears 
contradictive to propose that these cells are the modulators of tumor progression in castrate 
resistance. Nevertheless, three potential mechanisms have been proposed to explain poor 
outcome in prostate cancer patients (Sharifi et al., 2006): 1) Clonal selection to anti-androgen 
therapy may occur in transit-amplifying cells, which arise from the stem cells and divide a 
finite number of times until they become differentiated. Because of the limited growth of 
transit-amplifying cells, it is possible that CSCs may produce them in response to castration 
therapy; 2) Growth factor released by surrounding AR responsive cells may provide the 
resistance response to this type of therapy; and 3) CSCs produce cells that have a more 
differentiated morphology and express AR. 
The diagnosis and treatment of prostate cancer are currently based on clinical stage, biopsy 
Gleason grade, and serum PSA levels, which do not provide accurate information about the 
status of the tumor.  Several studies have identified by microarray, genetic signatures of 
prostate cancer that appear to provide a more accurate pathological distinction based on 
different degrees of severity (Lapointe et al., 2004; Singh et al., 2002). The identification of 
relevant cell signaling pathways signatures that are overexpressed in subpopulation with 
stem-like characteristics may also provide mechanistic information regarding their roles in 
tumor progression and metastasis (Birnie et al., 2008; Sharad et al., 2011). Therefore, it has 
been suggested that sophisticated therapy approaches involving specific DNA damaging 
agents in combination with DNA repair inhibitors may also improve available therapies 
against prostate cancer (Berry et al., 2008; Cano et al., 2007).  In addition, the combination of 
targeting cancer stem cells and androgen ablation may kill tumor cells and disrupt those 
cells that support tumor growth and survival (Berry et al., 2008). 
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6. Conclusions 
CSCs are believed to be a subpopulation of cancer cells that modulate malignancy and 
resistance to current anticancer treatments and, therefore, indicators of inferior prognosis. 
Although some of the mutated target genes have been identified, there is no clear evidence 
regarding the identification and isolation of cells that initiate tumor formation in solid 
malignant neoplasias. Therefore, even the role of CSC in tumorigenesis has been very well 
accepted, thought it remains controversial whether cancer mass arises specifically from stem 
cells. It is believed that in tumor bulk, there are particular subsets of cells (CSC) that may 
have the potential to promote tumor progression and resistance to conventional therapies. 
After completion of a treatment, the surviving tumor cells may have acquired even more 
mutations during the drug treatment. The additional genetic changes in this particular 
tumor subpopulation may explain why the conventional therapies fail in eradicating the 
cancer, a frequent concern in the diagnosis of prostate cancer and the rapid regrowth of the 
tumor but this time with a more aggressive phenotype. Since standard therapies applied to 
cancer are usually based on radiologic documentation of tumor shrinkage, the presence of 
CSCs may explain failure of tumor eradication. Thus, there is still an immediate priority for 
the identification of robust prognostic biomarkers to optimize cancer therapies to effectively 
target CSCs and their environment to improve prostate cancer treatment.  
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